The European Commission is preparing to withdraw ketoconazole-containing antifungal drugs from the market, the sale of which has already been banned by France, the European Medicines Agency announced on Tuesday.
The European Medicines Agency (EMA) has made public recommendations that ketoconazole-based drugs should be withdrawn from the entire European market.
The benefits of (taking) ketoconazole by the oral route do not compensate for the risk of liver damage in the case of treating mycoses with drugs containing this ingredient, according to the EMA message.
The agency has initiated a procedure aimed at restricting the use of these drugs across the EU, said AFP’s interlocutor.
If you are being treated with oral antifungal agents, pay close attention to their composition and check that they do not contain ketoconazole. The EMA recommends people treated with such drugs to ask their doctors to discuss alternative treatments.
The Agency notes that it is advisable to replace oral ketoconazole-based drugs with topical drugs, and the use of oral preparations may be continued in special cases, such as the treatment of Cushing’s syndrome. (PAP)
fit/ mc/